Management of Clinical Stage I Germ Cell Tumors.
Urol Clin North Am
; 46(3): 353-362, 2019 Aug.
Article
em En
| MEDLINE
| ID: mdl-31277730
ABSTRACT
Experience demonstrates multiple paths to cure for patients with clinical stage I testicular cancer. Because all options should provide a long-term disease-free rate near 100%, overall survival is no longer relevant in decision making, allowing practitioners to factor in quality of life, toxicity, cost, and impact on compliance. Surveillance for clinical stage I seminoma and clinical stage I nonseminoma has become the preferred option. The contrarian view is that a risk-adapted approach should persist, with surveillance for low-risk individuals and active therapy high-risk individuals. However, results obtained in unselected patients provide a strong argument against the need for such an approach.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Testiculares
/
Neoplasias Embrionárias de Células Germinativas
Tipo de estudo:
Prognostic_studies
Aspecto:
Patient_preference
Limite:
Humans
/
Male
Idioma:
En
Revista:
Urol Clin North Am
Ano de publicação:
2019
Tipo de documento:
Article